XRTX XORTX: רווח למניה בשנים עשר החודשים האחרונים

The 12-month EPS trend for XORTX Therapeutics Inc. (XRTX) reflects a lack of current earnings, as the company is in the clinical trial stage and relies on grants. -2.28 represents the current metric value. Growth prospects are based on the pricing power of orphan nephrology drugs, while investor confidence is bolstered by the high scientific expertise of the Canadian management team and transparent engagement with the FDA.
פילוחים אנליטיים ודוחות נתונים של חברת XORTX Therapeutics Inc. (XRTX)

XORTX Therapeutics Inc. operates in the high-risk biotech sector, where success depends on FDA approval and clinical trials. These expenses directly determine the net income distributable per common share. This indicator measures the rolling annual profit, adjusted for the total number of shares outstanding. Analyzing this value allows for an assessment of the real efficiency of capital generation. The trend of the annual net income per share visualizes business scalability and the risks of deep drawdowns.